secwatch.observer — SEC 8-K summary
======================================

Issuer:     PAVmed Inc. (PAVM)
CIK:        0001624326
Form:       8-K
Filed at:   2025-05-15T23:59:59+00:00
Accession:  0001641172-25-010536
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PAVmed Q1 GAAP net income $17.7M, adjusted loss $0.9M; Lucid raises $30.6M, cash >$40M
--------------------------------------------------------------------------------

- GAAP net income attributable to common stockholders $17.7M ($0.34 diluted EPS); non-GAAP adjusted loss $0.9M ($0.07 per share).
- Lucid Diagnostics (LUCD) recognized $0.8M EsoGuard revenue, processed 3,034 tests; raised $30.6M net from stock offerings, ended Q1 with over $40M pro forma cash.
- Veris Health completed financing, resumed development of implantable monitor; completed pilot with Ohio State's James Cancer Hospital, planning commercial partnership.
- PAVmed cash and cash equivalents $2.7M at March 31, 2025, up from $1.2M at Dec 31, 2024; operating expenses $5.5M including $1.0M stock-based comp.
- PAVmed seeking to expand into biopharma, evaluating clinical and late preclinical-stage assets for new subsidiary.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1624326/000164117225010536/0001641172-25-010536-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1624326/000164117225010536/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-010536

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer